Search

Compugen Ltd

Uždarymo kaina

2.31 -2.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.36

Max

2.38

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.408

55.725

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+110.08% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.5M

231M

Ankstesnė atidarymo kaina

4.84

Ankstesnė uždarymo kaina

2.31

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-27 23:51; UTC

Australia's Inflation Rate Expected to Rise to 4.1% Amid Global Economic Pressures Ahead of September 30 Release

2026-09-27 23:51; UTC

China's Non-Manufacturing PMI set for release on September 30, with forecasts indicating continued economic contraction at 49.3 amid cautious market sentiment and geopolitical concerns.

2026-09-27 23:51; UTC

Australia's RBA Trimmed Mean CPI YoY data release on September 30, 2026, is crucial for understanding core inflation trends amid global economic uncertainties and potential interest rate impacts.

2026-09-27 23:51; UTC

Australia's Building Permits Expected to Decline 0.9% in August Amid Mixed Trends and Economic Uncertainty

2026-09-27 23:51; UTC

China's NBS Manufacturing PMI Set for Release on September 30, Forecasted at 50.1 Amid Concerns Over Economic Recovery and Global Trade Relations.

2026-09-27 23:41; UTC

Bank of Japan to Release Key Monetary Policy Minutes Amid Optimism and Inflation Concerns on September 27, 2026

2026-09-27 23:41; UTC

U.S. September 2026 Unemployment Rate Release Forecasts Slight Increase to 4.2%, Amid Cautious Market Sentiment and Economic Policy Discussions

2026-09-27 23:41; UTC

U.S. Average Hourly Earnings Expected to Rise 0.3% in September, Influencing Fed's Rate Hike Decisions Amid Inflation Concerns

2026-09-27 23:41; UTC

U.S. Non-Farm Payrolls Expected to Add 100K Jobs in September Amid Cautious Optimism and Potential Market Volatility

2026-09-27 23:41; UTC

U.S. Labor Force Participation Rate Release on October 2, 2026, Expected Amidst Cautious Sentiment and Economic Challenges

2026-09-27 23:41; UTC

US Average Hourly Earnings Report on October 2 Could Signal Fed Rate Hikes Amid Inflation Concerns and Market Volatility.

2026-09-27 23:11; UTC

S&P Global Manufacturing PMI for South Korea Expected to Show Slight Decline Amid Economic Pressures and Resilient Industries

2026-09-27 23:11; UTC

U.S. Home Prices Expected to Rise 2.2% YoY Amidst Stabilizing Market Sentiment Despite Inflation Pressures

2026-09-27 23:11; UTC

Brazil's Industrial Production MoM Data Release on October 2, 2026: Market Anticipates Recovery Amid Ongoing Volatility.

2026-09-27 23:11; UTC

The EUR/CZK is trading roughly flat at the start of the new week, showing little change since Friday's close and reflecting stable performance.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

The Russell 2000 Index is lower, continuing a decline from Friday's close, amid Boeing's software glitch concerns and ongoing U.S.-China tariff discussions.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

The Nasdaq 100 Index is trading modestly lower amid reports of a U.S.-China tariff agreement on $30 billion in goods and geopolitical concerns.

2026-09-27 23:01; UTC

Macro News

The S&P 500 Index is trading lower amid macroeconomic developments, including the upcoming release of the Bank of Japan's July monetary policy minutes.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

Silver prices fell modestly amid discussions on Iran's military readiness and the upcoming release of the Bank of Japan's policy meeting minutes.

2026-09-27 23:01; UTC

Macro News

The AUD/USD is slightly lower as trading resumes, positioned near the lower end of its one-month range amid upcoming Bank of Japan minutes.

2026-09-27 23:01; UTC

Macro News

Oil (WTI) is advancing modestly as tensions in the Middle East escalate, with Iran signaling a potential disruption to global oil supply routes.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

Gold prices fell modestly, continuing a downward trend as geopolitical tensions and expectations of Bank of Japan minutes weigh on the market.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

Platinum prices are declining, continuing a downward trend influenced by silver's drop and geopolitical tensions affecting global energy markets.

2026-09-27 23:01; UTC

Correlated Moves
Macro News

The Dow Jones Index is lower amid mixed U.S. equities, influenced by U.S.-China tariff discussions and geopolitical concerns over Iran.

2026-09-27 23:01; UTC

U.S. Wholesale Inventories Expected to Rise 1.1% in August, Indicating Strong Business Confidence Amid Economic Uncertainties

2026-09-27 23:01; UTC

U.S. GDP Growth Rate for Q2 2026 Forecasted at 1.6% Amid Positive Foreign Investment and Trade Developments Ahead of September Release.

2026-09-27 23:01; UTC

U.S. GDP Price Index QoQ Final for Q2 2026 set to release on September 30, with a forecasted increase of 0.064%, amid positive market sentiment from U.S.-China trade negotiations aimed at reducing tariffs.

2026-09-27 23:01; UTC

PCE Price Index MoM for August 2026 set to release on September 30, with market expecting a 0.4% increase amid fluctuating inflation trends and rising foreign investment in U.S. equities.

2026-09-27 23:01; UTC

Upcoming PCE Price Index Release on September 30, 2026, May Influence U.S. Inflation Trends and Federal Reserve Policy Amid Mixed Market Sentiment.

2026-09-27 23:01; UTC

Personal Income MoM Data for August 2026 Forecasted to Rise by 0.4%, Indicating Cautious Optimism in U.S. Economic Growth Ahead of Release on September 30.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

110.08% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  110.08%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.